615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Updates in treatment for high-risk AML ASH denotes this abstract as clinically r

871 ASH denotes this abstract as clinically relevant

Andrew H. Wei, Hartmut Döhner, Hamid Sayar, et al.

The median OS in QUAZAR AML-001 was unchanged in both therapy arms after an additional follow-up of over 1 year. However, in contrast to the primary analysis, the tails of the Oral-AZA and PBO-OS curves showed a greater separation at later points in time. This suggests a sustained, long-term OS benefit with oral AZA. Long-term survival for QUAZAR AML-001 was associated with moderate risk cytogenetics and NPM1 mutations in AML Dx and the lack of a detectable MRD post-intensive chemotherapy.


872 ASH denotes this abstract as clinically relevant

Christian Recher, Christoph Rollig, Emilie Berard, et al.

This study, with a long median follow-up time and a large number of patients, shows: intensive chemotherapy remains the treatment strategy of choice even for AML patients aged 70 and older. Because it leads to better chances of survival compared to HMAs.


ASH denotes this abstract as clinically relevant

Hong-hu Zhu, Ya-fang Ma, Suning Chen, et al.

RIF plus retinoic acid as a post-remission treatment for high-risk APL is effective and safe.


874 ASH denotes this abstract as clinically relevant

Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, et al.

The study results show effective first-line treatment with TAG for BPDCN in all age cohorts, even in older patients and patients with a significant baseline disease. Thanks to a large number of permanent CRs, over 50 percent of patients could be bridged to HSCT, including older adults and patients with extensive baseline disease. Significant relapse-free survival has been observed in some non-transplant patients with TAG, up to 4 years in one patient. Side effects mainly occurring in cycle 1 were manageable. They were similar in older patients compared to younger patients.



Prapti Patel, Amy S. Ruppert, Uma Borate, et al.

IVO + AZA Tx resulted in a high CR/CRh/CRi rate in ND patients with IDH1m AML and aged 60 or more. There were no early deaths (60 days). The OS was 100 percent after one year. The compatibility of IVO + AZA is acceptable. No unexpected toxicities were recorded. Differentiation syndrome and QTc prolongation were most common with IVO (only one discontinuation of therapy). IVO + AZA achieved a higher CR/CRh / CRi rate compared to earlier studies with single drugs or more intensive chemotherapy approaches. This indicates a synergistic effect. This overall response rate is comparable to that recently for IVO + AZA in elderly patients with ND IDH1 mutated AML. A global phase 3 evaluation of IVO or placebo plus AZA (NCT03173248) is currently in progress.


876 ASH denotes this abstract as clinically relevant

Juliette Lambert, Pierre Peterlin, Cecile Pautas, et al.

The response rate in this study was 63 percent. According to the authors of the study, the GO-based regimen appears to be a valuable bridge-to-transplant option. The safety analysis corresponded to the already known safety profile of GO and chemotherapy.